Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q2 2023 call → NOWe need to determine if management describes successive engagements of the same kind coming in at progressively larger size. The transcript is about Delta Air Lines' Q2 2023 earnings. The business is airline operations, not deals/orders. The question asks about "deals, orders, contracts, projects, customers, sites, or programs" - but for an airline, the "same kind of business" might be capacity, routes, etc. However, the question is about unit size escalating. The transcript discusses revenue growth, capacity, premium revenue, etc. But does management convey that each new instance of essentially the same business is worth more? For example, are they signing larger contracts? No, they are an airline. They talk about capacity growth, but that's volume. They talk about premium revenue growing, but that's mix. They talk about corporate travel improving, but not about larger deals. They talk about international capacity, but not about larger individual engagements. The question is about the size of individual deals/orders/projects. Delta doesn't have such. They have routes, but they don't describe each new route being larger. They talk about capacity growth normalizing. No mention of escalating unit size. So answer NO. We need to be careful: the question is generic, but we must apply to the transcript. There is no mention of deals, orders, contracts, etc. So NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.